Cover Image
Market Research Report

Elephantiasis (Lymphatic Filariasis) - Pipeline Review, H2 2020

Published by Global Markets Direct Product code 302485
Published Content info 30 Pages
Delivery time: 1-2 business days
Price
Back to Top
Elephantiasis (Lymphatic Filariasis) - Pipeline Review, H2 2020
Published: July 31, 2020 Content info: 30 Pages
Description

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Elephantiasis - Pipeline Review, H2 2020, provides an overview of the Elephantiasis (Infectious Disease) pipeline landscape.

Elephantiasis commonly known as Lymphatic filariasis occurs when filarial parasites are transmitted to humans through mosquitoes. Infection is usually acquired in childhood causing hidden damage to the lymphatic system. Lymphatic filariasis is caused by infection with parasites classified as nematodes (roundworms) of the family Filariodidea. Symptoms include swelling, shaking chills, sweating, headaches, and vomiting. Treatment includes antibiotics.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Elephantiasis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Elephantiasis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Elephantiasis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Elephantiasis (Lymphatic Filariasis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I and Preclinical stages are 2 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Elephantiasis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Elephantiasis (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Elephantiasis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Elephantiasis (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Elephantiasis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Elephantiasis (Infectious Disease)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Elephantiasis (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Elephantiasis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Product Code: GMDHC12400IDB

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Elephantiasis (Lymphatic Filariasis) - Overview
  • Elephantiasis (Lymphatic Filariasis) - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Elephantiasis (Lymphatic Filariasis) - Therapeutics Assessment
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Elephantiasis (Lymphatic Filariasis) - Companies Involved in Therapeutics Development
  • AbbVie Inc
  • Eisai Co Ltd
  • Medicines Development Ltd
  • Pai Life Sciences Inc
  • Elephantiasis (Lymphatic Filariasis) - Drug Profiles
  • ABBV-4083 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AWZ-1066S - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • filariasis vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • lymphatic filariasis (multivalent) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • lymphatic filariasis (multivalent) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • moxidectin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Elephantiasis (Lymphatic Filariasis) - Dormant Projects
  • Elephantiasis (Lymphatic Filariasis) - Product Development Milestones
  • Featured News & Press Releases
  • Jan 08, 2019: New anti-Wolbachia drug with potential to treat onchocerciasis and lymphatic filariasis
  • Sep 14, 2018: £1.5M to develop candidate drug to treat onchocerciasis and lymphatic filariasis
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

List of Tables

  • Number of Products under Development for Elephantiasis (Lymphatic Filariasis), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Elephantiasis (Lymphatic Filariasis) - Pipeline by AbbVie Inc, H2 2020
  • Elephantiasis (Lymphatic Filariasis) - Pipeline by Eisai Co Ltd, H2 2020
  • Elephantiasis (Lymphatic Filariasis) - Pipeline by Medicines Development Ltd, H2 2020
  • Elephantiasis (Lymphatic Filariasis) - Pipeline by Pai Life Sciences Inc, H2 2020
  • Elephantiasis (Lymphatic Filariasis) - Dormant Projects, H2 2020

List of Figures

List of Figures

  • Number of Products under Development for Elephantiasis (Lymphatic Filariasis), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products by Stage and Routes of Administration, H2 2020
  • Number of Products by Molecule Types, H2 2020
  • Number of Products by Stage and Molecule Types, H2 2020
Back to Top